Why did adjusted EPS grow 28% when GAAP EPS grew only 8.3%?

Adjusted EPS excludes items management considers outside ordinary operations. The largest exclusion is $570M of pre-tax purchase accounting adjustments ($1.96 per share), mainly amortization of intangibles from acquisitions such as Edwards' Critical Care business. Restructuring, product and legal items, and related tax effects also are excluded. Investors should weigh GAAP results alongside the adjusted figures, since excluded items are real costs and the acquisition-related amortization is recurring in nature.

What exactly is BD proposing to separate, and when?

BD's board authorized management to pursue a separation of the Biosciences and Diagnostic Solutions business. The business is expected to have about $3.4B of FY24 revenue, over 80% recurring revenue, and roughly 30% adjusted EBITDA margins. BD expects to announce specifics by the end of fiscal 2025 and targets completing the transaction in fiscal 2026. Possible structures include a Reverse Morris Trust, sale, or spin-off, and completion depends on board approval, regulatory clearances, and SEC requirements. No assurance was given on form, terms, or timing.

Why did guidance for GAAP revenue decline even though the company raised EPS guidance?

The GAAP revenue range fell to $21.7–$21.9B from $21.9–$22.1B. The filing attributes the change to a restated base: fiscal 2024 reported revenue was adjusted for a $67M accrual tied to Italian medical device payback legislation and another legal matter, which relate mainly to prior years. Organic revenue growth guidance (4.0%–4.5% FXN) was unchanged, so the revenue adjustment and currency movements, not the underlying business, account for most of the change.

What are the key risks from the $175 million SEC-related charge and the Alaris pump issues?

BD recorded a $175M charge to accrue an estimated liability for an SEC investigation into reporting issues involving BD Alaris infusion pumps in disclosures made before 2021. The forward-looking statements also flag the timing of the Alaris replacement and return to market in the U.S., plus FDA engagement, as risks. The charge is excluded from adjusted EPS, so investors should consider the cash and reputational implications separately from the adjusted figures.

How is BD's balance sheet and capital return position after the quarter?

Total debt fell to about $18.8B from $20.1B, including $875M of debt payments, and cash and equivalents dropped to $711M from $1.717B. BD repurchased $750M of stock in the quarter and paid $302M in dividends, and the board authorized up to 10 million additional shares. Interest expense rose 39% to $155M, reflecting financing costs for the Advanced Patient Monitoring acquisition. Post-separation, New BD intends to maintain an investment-grade rating while continuing dividends and buybacks.

BDX 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed February 5, 2025. Cited figures are marked; the original filing is the authoritative source.

BD (Becton, Dickinson and Company) reported fiscal Q1 2025 results (quarter ended December 31, 2024) that beat its internal expectations on revenue, margin, and earnings.

Revenue rose 9.8% reported to $5.168 billion^a (9.6% currency-neutral, 3.9% organic). GAAP diluted EPS was $1.04 (up 8.3%), while adjusted diluted EPS was $3.43 (up 28.0%). The reported-to-adjusted gap is large, driven mainly by $570 million in pre-tax purchase accounting adjustments, largely from the Edwards Lifesciences Critical Care (Advanced Patient Monitoring) acquisition.

Net income was $303 million^b versus $281 million a year earlier, and operating income rose only 3.2%. Interest expense climbed 39% to $155 million, reflecting acquisition financing. BD raised the midpoint of its FY25 adjusted EPS guidance to $14.30 to $14.60 (about 10% growth), an operational increase of $0.175 that more than offset roughly $0.15 of translational currency headwind.

GAAP revenue guidance was lowered to $21.7 to $21.9 billion^c from $21.9 to $22.1 billion, largely because the prior-year guidance base was restated after a $67 million revenue adjustment tied to Italian medical device payback legislation. The most consequential disclosure is the board's unanimous authorization for management to pursue a separation of the Biosciences and Diagnostic Solutions business from the rest of BD. Management plans to provide more specifics by the end of fiscal 2025 and to target completion in fiscal 2026.

Options under consideration include a Reverse Morris Trust, sale, or spin-off. The separated business is expected to generate about $3.4 billion^d in fiscal 2024 revenue with roughly 30% adjusted EBITDA margins, while "New BD" would have about $17.8 billion of comparable revenue organized into four segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional. BD also postponed its February 26, 2025 Investor Day.

Investors should note that the separation carries execution risk, and no assurance was given on form, terms, or timing. The filing also disclosed a $175 million accrual for an SEC investigation related to reporting issues involving BD Alaris infusion pumps. Balance sheet metrics show total debt falling to about $18.8 billion from $20.1 billion after $875 million of debt repayments in the quarter.

Cash and equivalents fell to $711 million from $1.717 billion, and BD repurchased $750 million of stock. Management also authorized up to 10 million additional repurchase shares.

02—Key points

Key Highlights

Revenue of $5.168B grew 9.8% reported and 3.9% organic; BD Medical (+17.3%) led, boosted by the Advanced Patient Monitoring acquisition, while BD Life Sciences grew only 0.7%.
GAAP diluted EPS was $1.04 (+8.3%) versus adjusted diluted EPS of $3.43 (+28.0%); the $1.96 purchase-accounting adjustment per share is the main driver of the gap.
FY25 adjusted diluted EPS guidance was raised at the midpoint to $14.30–$14.60 (~10% growth), absorbing about $0.15 of FX headwind.
FY25 GAAP revenue guidance was lowered to $21.7–$21.9B from $21.9–$22.1B, reflecting a restated prior-year base after a $67M Italian payback-legislation accrual.
The board authorized management to pursue a separation of Biosciences and Diagnostic Solutions (~$3.4B FY24 revenue, ~30% adjusted EBITDA margin), with details due by end of FY25 and completion targeted for FY26.
The company postponed its February 26, 2025 Investor Day to focus on the separation transaction.
A $175M accrual was recorded for an SEC investigation tied to Alaris pump reporting; debt fell by $875M in the quarter and $750M of shares were repurchased, with cash declining to $711M.

03—Questions

Frequently Asked Questions

Why did adjusted EPS grow 28% when GAAP EPS grew only 8.3%?
Adjusted EPS excludes items management considers outside ordinary operations. The largest exclusion is $570M of pre-tax purchase accounting adjustments ($1.96 per share), mainly amortization of intangibles from acquisitions such as Edwards' Critical Care business. Restructuring, product and legal items, and related tax effects also are excluded. Investors should weigh GAAP results alongside the adjusted figures, since excluded items are real costs and the acquisition-related amortization is recurring in nature.
What exactly is BD proposing to separate, and when?
BD's board authorized management to pursue a separation of the Biosciences and Diagnostic Solutions business. The business is expected to have about $3.4B of FY24 revenue, over 80% recurring revenue, and roughly 30% adjusted EBITDA margins. BD expects to announce specifics by the end of fiscal 2025 and targets completing the transaction in fiscal 2026. Possible structures include a Reverse Morris Trust, sale, or spin-off, and completion depends on board approval, regulatory clearances, and SEC requirements. No assurance was given on form, terms, or timing.
Why did guidance for GAAP revenue decline even though the company raised EPS guidance?
The GAAP revenue range fell to $21.7–$21.9B from $21.9–$22.1B. The filing attributes the change to a restated base: fiscal 2024 reported revenue was adjusted for a $67M accrual tied to Italian medical device payback legislation and another legal matter, which relate mainly to prior years. Organic revenue growth guidance (4.0%–4.5% FXN) was unchanged, so the revenue adjustment and currency movements, not the underlying business, account for most of the change.
What are the key risks from the $175 million SEC-related charge and the Alaris pump issues?
BD recorded a $175M charge to accrue an estimated liability for an SEC investigation into reporting issues involving BD Alaris infusion pumps in disclosures made before 2021. The forward-looking statements also flag the timing of the Alaris replacement and return to market in the U.S., plus FDA engagement, as risks. The charge is excluded from adjusted EPS, so investors should consider the cash and reputational implications separately from the adjusted figures.
How is BD's balance sheet and capital return position after the quarter?
Total debt fell to about $18.8B from $20.1B, including $875M of debt payments, and cash and equivalents dropped to $711M from $1.717B. BD repurchased $750M of stock in the quarter and paid $302M in dividends, and the board authorized up to 10 million additional shares. Interest expense rose 39% to $155M, reflecting financing costs for the Advanced Patient Monitoring acquisition. Post-separation, New BD intends to maintain an investment-grade rating while continuing dividends and buybacks.

04—Continue

← View all 8-K filings